Cooperative Research and Development Agreement (CRADA) Opportunity With the Department of Homeland Security for the Efficacy Testing of Vaporous Hydrogen Peroxide (VHP) and Chlorine Dioxide (ClO2, 48165-48166 [2012-19723]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 156 / Monday, August 13, 2012 / Notices
Health, 615 Davis Dr., KEY615/3112,
Research Triangle Park, NC 27709, (919) 541–
4980, collman@niehs.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.niehs.nih.gov/dert/c-agenda.htm, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation-Health Risks from Environmental
Exposures; 93.142, NIEHS Hazardous Waste
Worker Health and Safety Training; 93.143,
NIEHS Superfund Hazardous Substances—
Basic Research and Education; 93.894,
Resources and Manpower Development in
the Environmental Health Sciences; 93.113,
Biological Response to Environmental Health
Hazards; 93.114, Applied Toxicological
Research and Testing, National Institutes of
Health, HHS)
Dated: August 7, 2012.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–19715 Filed 8–10–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Application (P01).
Date: September 6, 2012.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Mar<15>2010
16:29 Aug 10, 2012
Jkt 226001
Place: Fernwood (Rockledge Campus),
10401 Fernwood Rd., Room 2C05, Bethesda,
MD 20892, (Telephone Conference Call)
Contact Person: Kelly Y. Poe, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 6700–B
Rockledge Drive, MDS–7616, Bethesda, MD
20892–7616, 301–451–2639,
poeky@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Clinical Trials in Organ
Transplantation in Children.
Date: September 10–11, 2012.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: James T. Snyder, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
DHHS/NIH/NIAID, 6700B Rockledge Drive,
MSC 7616, Room # 3257, Bethesda, MD
20892, 301–435–1614, james.snyder@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Application (P01).
Date: September 12, 2012.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Fernwood (Rockledge Campus),
10401 Fernwood Rd., Room 2C05, Bethesda,
MD 20892, (Telephone Conference Call).
Contact Person: Kelly Y. Poe, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 6700–B
Rockledge Drive, MDS–7616, Bethesda, MD
20892–7616, 301–451–2639,
poeky@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 7, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–19716 Filed 8–10–12; 8:45 am]
BILLING CODE 4140–01–P
48165
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Integrative
and Functional Neurobiology.
Date: September 5, 2012.
Time: 2:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Center for Scientific Review, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Wei-Qin Zhao, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5181
MSC 7846, Bethesda, MD 20892–7846, 301–
435–1236, zhaow@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 7, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–19717 Filed 8–10–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2012–0044]
Cooperative Research and
Development Agreement (CRADA)
Opportunity With the Department of
Homeland Security for the Efficacy
Testing of Vaporous Hydrogen
Peroxide (VHP) and Chlorine Dioxide
(ClO2) Against Foot and Mouth Disease
Virus (FMDV) and African Swine Fever
Virus (ASFV)
Science and Technology
Directorate, Plum Island Animal Disease
Center, Department of Homeland
Security.
ACTION: Notice of intent.
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
The Department of Homeland
Security Science and Technology
Directorate (DHS S&T), through its Plum
Island Animal Disease Center (PIADC),
is seeking collaborators to aid DHS S&T
in conducting validation testing on the
ability of VHP and ClO2 to achieve
sufficient biological load reduction
against live FMDV and ASFV. PIADC
operates a Biosafety Level 3 (BSL–3)
facility working primarily with high
consequence foreign animal diseases.
The nature of this work makes it
SUMMARY:
E:\FR\FM\13AUN1.SGM
13AUN1
48166
Federal Register / Vol. 77, No. 156 / Monday, August 13, 2012 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
paramount to ensure the effective and
thorough decontamination of all
material exiting the bio containment
area within the facility. Rising health
concerns and process efficiency/turnaround time with the use of
formaldehyde gas (the current
fumigation method used against FMDV
and ASFV) are key driving factors in
validating an alternative fumigation
method. The fumigation method(s) will
ultimately be used to decontaminate
sensitive equipment and electronics,
other material within the bio
containment area, sealed portions of the
facility, biological safety cabinets and
perform in-place decontamination of
heating, ventilation, and cooling
(HVAC) HEPA filtration systems. The
role of the collaborator(s) in this CRADA
will be to provide PIADC with the
materials, equipment, and technological
expertise to support accurate and
reliable efficacy testing using VHP and
ClO2. DHS S&T is seeking CRADA
collaborators that own the technological
components for, have the technological
expertise in, and have proven track
records of success in the fields of VHP
and ClO2 decontamination validation
studies. The proposed term of the
CRADA can be up to eighteen (18)
months.
DATES: Submit comments on or before
September 14, 2012.
ADDRESSES: Mail comments and
requests to participate to Doug Ports,
(PO Box 848, Greenport, NY 11944).
Submit electronic comments and other
data to Douglas.Ports@hq.dhs.gov.
FOR FURTHER INFORMATION CONTACT:
Information on DHS CRADAs: Marlene
Owens, (202) 254–6671. Information on
proposed technical effort: Doug Ports,
(631) 323–3210.
SUPPLEMENTARY INFORMATION:
Efficacy Testing Plan
The target agents (FMDV and ASFV)
and test microorganisms (Bacillus
subtilis, Vaccinia Virus, Geobacillius
stearothermophilus, and potentially
other commercially available spore
strips) will be used to test the efficacy
of VHP and ClO2 on various surfaces
including balsa wood, stainless steel,
glass, and paper. Phase I of the testing
is set to take place at a federal laboratory
facility against the test microorganisms,
requiring successful results prior to
moving on to Phase II. Phase II testing
will take place at PIADC (Plum Island,
NY) against both the test
microorganisms and target agents. Phase
I and Phase II efficacy testing will not
require the VHP or ClO2 generators to
enter the bio containment area;
however, components or probes that do
VerDate Mar<15>2010
16:29 Aug 10, 2012
Jkt 226001
enter the bio containment area will need
to be decontaminated using a validated
method prior to removal. Testing and
decontamination validation will take
place using pre-approved methods
agreed upon between federal and nonfederal personnel. Mutual benefits to
both federal and non-federal
collaborators include the opportunity to
support the Homeland Security
Enterprise in protecting the United
States from internal and external foreign
animal disease threats and response
capabilities. Specifically, DHS S&T is
interested in validated alternatives to
formaldehyde fumigation with respect
to outbreak control, infection control,
and decontamination for FMDV and
AFSV releases. The collaborators will
also have the opportunity to test their
decontamination methods directly
against live FMDV and ASFV at the only
laboratory in the United States, and one
of few in the world, that works with live
FMDV. Efficacy testing data and results
may be published in scientific journals
by or under the guidance of federal
personnel.
Period of Performance
Once CRADA collaborators have been
selected, finalized Phase I testing is
expected to take approximately 3
months. Contingent on Phase I testing
results, Phase II testing is expected to
take an additional 6 months and data
consolidation, analysis, and results
finalization is expected to take another
3 months following.
Selection Criteria
The Plum Island Animal Disease
Center (PIADC) reserves the right to
select CRADA collaborators for all,
some, or none of the proposals in
response to this notice. PIADC will
provide no funding for reimbursement
of proposal development costs.
Proposals (or any other material)
submitted in response to this notice will
not be returned. Proposals submitted are
expected to be unclassified.
PIADC will select proposals at its sole
discretion on the basis of:
i. How well the proposal
communicates the collaborators’
understanding of and ability to meet the
CRADAs goals and proposed timeline
ii. How well the proposal addresses
the following criteria:
a. Capability of the collaborator to
provide equipment and materials for
proposed Phase I and Phase II efficacy
testing.
b. Capability of the collaborator to
provide on-site and remote
technological expertise, within a
reasonable time period and for a
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
reasonable duration, for Phase I and
Phase II efficacy testing.
Participation in this CRADA does not
imply the future purchase of any
materials, equipment or services from
the collaborating entities; however, nonFederal CRADA participants will not be
excluded from any future PIADC
procurements based solely on their
participation in this CRADA.
Authority: CRADAs are authorized by the
Federal Technology Transfer Act of 1986, as
amended and codified by 15 U.S.C. 3710a.
DHS, as an executive agency under 5 U.S.C.
105, is a Federal agency for the purposes of
15 U.S.C. 3710a and may enter into a
CRADA. DHS delegated the authority to
conduct CRADAs to the Science and
Technology Directorate and its laboratories.
Dated: August 7, 2012
James Johnson,
Director, Office of National Laboratories.
[FR Doc. 2012–19723 Filed 8–10–12; 8:45 am]
BILLING CODE 9110–9F–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–4067–
DR; Docket ID FEMA–2012–0002]
Colorado; Amendment No. 2 to Notice
of a Major Disaster Declaration
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
This notice amends the notice
of a major disaster declaration for the
State of Colorado (FEMA–4067–DR),
dated June 28, 2012, and related
determinations.
SUMMARY:
DATES:
Effective Date: August 6, 2012.
FOR FURTHER INFORMATION CONTACT:
Peggy Miller, Office of Response and
Recovery, Federal Emergency
Management Agency, 500 C Street SW.,
Washington, DC 20472, (202) 646–3886.
SUPPLEMENTARY INFORMATION: The notice
of a major disaster declaration for the
State of Colorado is hereby amended to
include the Hazard Mitigation Grant
Program for the following areas among
those areas determined to have been
adversely affected by the event declared
a major disaster by the President in his
declaration of June 28, 2012.
All counties in the State of Colorado are
eligible to apply for assistance under the
Hazard Mitigation Grant Program.
(The following Catalog of Federal Domestic
Assistance Numbers (CFDA) are to be used
for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora
E:\FR\FM\13AUN1.SGM
13AUN1
]]>Agencies
[Federal Register Volume 77, Number 156 (Monday, August 13, 2012)]
[Notices]
[Pages 48165-48166]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-19723]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HOMELAND SECURITY
[Docket No. DHS-2012-0044]
Cooperative Research and Development Agreement (CRADA)
Opportunity With the Department of Homeland Security for the Efficacy
Testing of Vaporous Hydrogen Peroxide (VHP) and Chlorine Dioxide
(ClO2) Against Foot and Mouth Disease Virus (FMDV) and
African Swine Fever Virus (ASFV)
AGENCY: Science and Technology Directorate, Plum Island Animal Disease
Center, Department of Homeland Security.
ACTION: Notice of intent.
-----------------------------------------------------------------------
SUMMARY: The Department of Homeland Security Science and Technology
Directorate (DHS S&T), through its Plum Island Animal Disease Center
(PIADC), is seeking collaborators to aid DHS S&T in conducting
validation testing on the ability of VHP and ClO2 to achieve
sufficient biological load reduction against live FMDV and ASFV. PIADC
operates a Biosafety Level 3 (BSL-3) facility working primarily with
high consequence foreign animal diseases. The nature of this work makes
it
[[Page 48166]]
paramount to ensure the effective and thorough decontamination of all
material exiting the bio containment area within the facility. Rising
health concerns and process efficiency/turn-around time with the use of
formaldehyde gas (the current fumigation method used against FMDV and
ASFV) are key driving factors in validating an alternative fumigation
method. The fumigation method(s) will ultimately be used to
decontaminate sensitive equipment and electronics, other material
within the bio containment area, sealed portions of the facility,
biological safety cabinets and perform in-place decontamination of
heating, ventilation, and cooling (HVAC) HEPA filtration systems. The
role of the collaborator(s) in this CRADA will be to provide PIADC with
the materials, equipment, and technological expertise to support
accurate and reliable efficacy testing using VHP and ClO2.
DHS S&T is seeking CRADA collaborators that own the technological
components for, have the technological expertise in, and have proven
track records of success in the fields of VHP and ClO2
decontamination validation studies. The proposed term of the CRADA can
be up to eighteen (18) months.
DATES: Submit comments on or before September 14, 2012.
ADDRESSES: Mail comments and requests to participate to Doug Ports, (PO
Box 848, Greenport, NY 11944). Submit electronic comments and other
data to Douglas.Ports@hq.dhs.gov.
FOR FURTHER INFORMATION CONTACT: Information on DHS CRADAs: Marlene
Owens, (202) 254-6671. Information on proposed technical effort: Doug
Ports, (631) 323-3210.
SUPPLEMENTARY INFORMATION:
Efficacy Testing Plan
The target agents (FMDV and ASFV) and test microorganisms (Bacillus
subtilis, Vaccinia Virus, Geobacillius stearothermophilus, and
potentially other commercially available spore strips) will be used to
test the efficacy of VHP and ClO2 on various surfaces
including balsa wood, stainless steel, glass, and paper. Phase I of the
testing is set to take place at a federal laboratory facility against
the test microorganisms, requiring successful results prior to moving
on to Phase II. Phase II testing will take place at PIADC (Plum Island,
NY) against both the test microorganisms and target agents. Phase I and
Phase II efficacy testing will not require the VHP or ClO2
generators to enter the bio containment area; however, components or
probes that do enter the bio containment area will need to be
decontaminated using a validated method prior to removal. Testing and
decontamination validation will take place using pre-approved methods
agreed upon between federal and non-federal personnel. Mutual benefits
to both federal and non-federal collaborators include the opportunity
to support the Homeland Security Enterprise in protecting the United
States from internal and external foreign animal disease threats and
response capabilities. Specifically, DHS S&T is interested in validated
alternatives to formaldehyde fumigation with respect to outbreak
control, infection control, and decontamination for FMDV and AFSV
releases. The collaborators will also have the opportunity to test
their decontamination methods directly against live FMDV and ASFV at
the only laboratory in the United States, and one of few in the world,
that works with live FMDV. Efficacy testing data and results may be
published in scientific journals by or under the guidance of federal
personnel.
Period of Performance
Once CRADA collaborators have been selected, finalized Phase I
testing is expected to take approximately 3 months. Contingent on Phase
I testing results, Phase II testing is expected to take an additional 6
months and data consolidation, analysis, and results finalization is
expected to take another 3 months following.
Selection Criteria
The Plum Island Animal Disease Center (PIADC) reserves the right to
select CRADA collaborators for all, some, or none of the proposals in
response to this notice. PIADC will provide no funding for
reimbursement of proposal development costs. Proposals (or any other
material) submitted in response to this notice will not be returned.
Proposals submitted are expected to be unclassified.
PIADC will select proposals at its sole discretion on the basis of:
i. How well the proposal communicates the collaborators'
understanding of and ability to meet the CRADAs goals and proposed
timeline
ii. How well the proposal addresses the following criteria:
a. Capability of the collaborator to provide equipment and
materials for proposed Phase I and Phase II efficacy testing.
b. Capability of the collaborator to provide on-site and remote
technological expertise, within a reasonable time period and for a
reasonable duration, for Phase I and Phase II efficacy testing.
Participation in this CRADA does not imply the future purchase of any
materials, equipment or services from the collaborating entities;
however, non-Federal CRADA participants will not be excluded from any
future PIADC procurements based solely on their participation in this
CRADA.
Authority: CRADAs are authorized by the Federal Technology
Transfer Act of 1986, as amended and codified by 15 U.S.C. 3710a.
DHS, as an executive agency under 5 U.S.C. 105, is a Federal agency
for the purposes of 15 U.S.C. 3710a and may enter into a CRADA. DHS
delegated the authority to conduct CRADAs to the Science and
Technology Directorate and its laboratories.
Dated: August 7, 2012
James Johnson,
Director, Office of National Laboratories.
[FR Doc. 2012-19723 Filed 8-10-12; 8:45 am]
BILLING CODE 9110-9F-P
